The FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
for the drug, said the medication is such an improvement over current therapies that she doubts the IV administration will discourage its use.
“For women suffering, you can say, ‘You can come in and be treated and in 2.5 days it can go away, and not come back,’ ” she said., “a breakdown product” of the hormone progesterone that affects the GABA neurotransmitters, which have a role in mood regulation, Meltzer-Brody said. Its exact mechanism of action is unknown.
The FDA's advisory committee recommended approval of brexanolone in early November, but the agency delayed the green light to evaluate a safety concern: A small number of women who received the drug lost consciousness. , a psychiatrist at UC San Francisco, said she was encouraged to see an entirely new approach to medication for depression and, in particular, a product aimed specifically at women's mental health.She said mild to moderate cases can be missed because the fatigue and sleeplessness that accompany the arrival of a new baby are also some of the physical symptoms of depression.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Read more »
Sage stock rises after FDA approves first postpartum depression treatment Zulresso
Read more »
FDA approves first postpartum depression drugThe US Food and Drug Administration announced on Tuesday it has approved the first medication specifically targeted to treat postpartum depression in women. The treatment is administered as a single 60-hour IV drip, and could offer new hope to moms.
Read more »
‘Transformative’: FDA approves first drug for postpartum depressionBrexanolone is not a pill. The drug is delivered intravenously over the course of a 60-hour infusion, meaning it must be administered in a medically supervised setting, such as a skilled facility or a hospital, rather than at patients’ homes.
Read more »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Read more »
FDA tightens restrictions on e-cigarette sales and fruity flavors to stem teen vapingFDA tightens restrictions on e-cigarette sales and fruity flavors to stem teen vaping.
Read more »
U.S. proposes stricter curbs on e-cigarette salesThe U.S. Food and Drug Administration (FDA) on Wednesday released formal plans t...
Read more »